ABBVIE INC.

ABBV

Real-time Estimate - 10/22 05:28:57 pm
84.475USD	+1.91%

Prev.	82.8900
Open	83.0200
High	84.8900
Low	82.9200
Volume	9 776 877

3d ago	AbbVie : Seeks U.S., European OK of Rinvoq in Eczema
3d ago	AbbVie : VENCLEXTA Receives FDA Full Approval for Acute Myeloid Leukemia
3d ago	AbbVie : Submits Regulatory Applications to FDA and EMA for RINVOQ™...
3d ago	ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)

	Short Term	Mid-Term	Long Term
Trend	Bearish	Neutral	Bullish
Resistance	86,3	101	101
Spread/Res.	-2,3%	-16%	-16%
Spread/Supp.	1,7%	3,0%	1,8%
Support	82,9	81,9	82,8

Sales 2020	45 364 M - -
Net income 2020	10 285 M - -
Net Debt 2020	73 871 M - -
P/E ratio 2020	15,7x
Yield 2020	5,96%

Capitalization	149 B 149 B -
EV / Sales 2020	4,91x
EV / Sales 2021	3,97x
Nbr of Employees	47 000
Free-Float	98,5%

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with...

>> Read more

Sector :

Pharmaceuticals - NEC

Calendar :

2020-10-30 Earnings Release

Trading Rating :

Investor Rating :

Mean consensus	BUY
Number of Analysts	19
Average target price	109,21 $
Last Close Price	82,89 $
Spread / Highest target	53,2%
Spread / Average Target	31,8%
Spread / Lowest Target	15,8%